50 related articles for article (PubMed ID: 37897298)
1. Alternative genetic alterations of MYC, BCL2, and/or BCL6 in high-grade B-cell lymphoma (HGBL) and diffuse large B-cell lymphoma (DLBCL): Can we identify different prognostic subgroups?
Blomme S; De Paepe P; Devos H; Emmerechts J; Snauwaert S; Cauwelier B
Genes Chromosomes Cancer; 2024 Jan; 63(1):e23211. PubMed ID: 37897298
[TBL] [Abstract][Full Text] [Related]
2. Mutational, immune microenvironment, and clinicopathological profiles of diffuse large B-cell lymphoma and follicular lymphoma with BCL6 rearrangement.
Carreras J; Ikoma H; Kikuti YY; Miyaoka M; Hiraiwa S; Tomita S; Kondo Y; Ito A; Nagase S; Miura H; Kawada H; Roncador G; Campo E; Hamoudi R; Nakamura N
Virchows Arch; 2024 Apr; 484(4):657-676. PubMed ID: 38462571
[TBL] [Abstract][Full Text] [Related]
3. Case report: Mutation evolution in a patient with TdT positive high grade B cell lymphoma with MYC and BCL2 rearrangements following the treatment of concurrent follicular lymphoma and diffuse large B-cell lymphoma.
Zhang F; Chen Y; Cui Q; Ge Y; Liu Y
Discov Oncol; 2024 Apr; 15(1):129. PubMed ID: 38662249
[TBL] [Abstract][Full Text] [Related]
4. High-grade B-cell lymphoma with a quadruple-hit genetic profile including concurrent MYC, BCL2, BCL6, and CCND1 gene rearrangements.
Gagnon MF; Meyer RG; Weaver EJ; Wood AJ; Dupuy DA; Menachery SJ; Shi M; Baughn LB; Ketterling RP; Peterson JF
Lab Med; 2024 Mar; ():. PubMed ID: 38522075
[TBL] [Abstract][Full Text] [Related]
5. Cytogenetic and pathologic characterization of MYC-rearranged B-cell lymphomas in pediatric and young adult patients.
Gagnon MF; Bruehl FK; Sill DR; Meyer RG; Greipp PT; Hoppman NL; Xu X; Baughn LB; Peterson JF; McPhail ED; Ketterling RP; King RL
J Hematop; 2024 Apr; ():. PubMed ID: 38561469
[TBL] [Abstract][Full Text] [Related]
6. Clinical relevance of MYC/BCL2 expression and cell of origin in patients with diffuse large b-cell lymphoma treated with autologous transplant.
Al-Juhaishi T; Wang Y; Milton DR; Xu-Monette ZY; Jabbour E; Daher M; Im JS; Bashir Q; Iyer SP; Marin D; Olson AL; Popat U; Qazilbash M; Rondon G; Gulbis AM; Champlin RE; Young KH; Khouri IF
Bone Marrow Transplant; 2023 Sep; 58(9):1000-1007. PubMed ID: 37198234
[TBL] [Abstract][Full Text] [Related]
7. Genetic modification of primary human B cells to model high-grade lymphoma.
Caeser R; Di Re M; Krupka JA; Gao J; Lara-Chica M; Dias JML; Cooke SL; Fenner R; Usheva Z; Runge HFP; Beer PA; Eldaly H; Pak HK; Park CS; Vassiliou GS; Huntly BJP; Mupo A; Bashford-Rogers RJM; Hodson DJ
Nat Commun; 2019 Oct; 10(1):4543. PubMed ID: 31586074
[TBL] [Abstract][Full Text] [Related]
8. Motive and Opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements-an LLMPP study.
Hilton LK; Collinge BJ; Ben-Neriah S; Alduaij W; Shaalan H; Weng A; Cruz M; Slack GW; Farinha P; Miyata-Takata T; Boyle M; Meissner B; Cook JR; Ondrejka SL; Ott G; Rosenwald A; Campo E; Amador C; Greiner TC; Raess PW; Song JY; Inghirami GG; Jaffe ES; Weisenburger DD; Chan WC; Beiske K; Fu K; Delabie J; Pittaluga S; Iqbal J; Wright G; Sehn LH; Savage KJ; Mungall AJ; Feldman AL; Staudt LM; Steidl C; Rimsza LM; Morin RD; Scott DW
Blood; 2024 May; ():. PubMed ID: 38701426
[TBL] [Abstract][Full Text] [Related]
9. High-grade B-cell lymphoma with MYC and BCL2 rearrangements presenting as a cervical mass.
Lin C; Kuma L; Shen L
Pathology; 2024 Jun; 56(4):588-590. PubMed ID: 37940480
[No Abstract] [Full Text] [Related]
10. Diffuse Large B Cell Lymphoma Cell Line U-2946: Model for MCL1 Inhibitor Testing.
Quentmeier H; Drexler HG; Hauer V; MacLeod RA; Pommerenke C; Uphoff CC; Zaborski M; Berglund M; Enblad G; Amini RM
PLoS One; 2016; 11(12):e0167599. PubMed ID: 27907212
[TBL] [Abstract][Full Text] [Related]
11. Aggressive B-cell non-Hodgkin lymphomas: a report of the lymphoma workshop of the 20th meeting of the European Association for Haematopathology.
Rodriguez-Pinilla SM; Dojcinov S; Dotlic S; Gibson SE; Hartmann S; Klimkowska M; Sabattini E; Tousseyn TA; de Jong D; Hsi ED
Virchows Arch; 2024 Jan; 484(1):15-29. PubMed ID: 37530792
[TBL] [Abstract][Full Text] [Related]
12. The genetic landscape of histologically transformed marginal zone lymphomas.
Li A; Yi H; Deng S; Ruan M; Xu P; Huo Y; Lu H; Shen X; Ouyang B; Cai M; Xu H; Wang Z; Zhang L; Zhu L; Peng Q; Gu Y; Xie J; Wang Y; Dong L; Liu Z; Wang C
Cancer; 2024 Apr; 130(8):1246-1256. PubMed ID: 37941429
[TBL] [Abstract][Full Text] [Related]
13. Super-enhancer hypermutation alters oncogene expression in B cell lymphoma.
Bal E; Kumar R; Hadigol M; Holmes AB; Hilton LK; Loh JW; Dreval K; Wong JCH; Vlasevska S; Corinaldesi C; Soni RK; Basso K; Morin RD; Khiabanian H; Pasqualucci L; Dalla-Favera R
Nature; 2022 Jul; 607(7920):808-815. PubMed ID: 35794478
[TBL] [Abstract][Full Text] [Related]
14. How Many Tests Does It Take to Diagnose a Triple-Hit B-Lymphoblastic Lymphoma? (Hint, It's A Lot).
Das M; Tsuchiya KD; Bohling SD; Davis B; Hwang S; Gardner RA; Chisholm KM
Pediatr Dev Pathol; 2024; 27(2):193-197. PubMed ID: 38032739
[TBL] [Abstract][Full Text] [Related]
15. Delineating the mechanism of fragility at BCL6 breakpoint region associated with translocations in diffuse large B cell lymphoma.
Gopalakrishnan V; Roy U; Srivastava S; Kariya KM; Sharma S; Javedakar SM; Choudhary B; Raghavan SC
Cell Mol Life Sci; 2024 Jan; 81(1):21. PubMed ID: 38196006
[TBL] [Abstract][Full Text] [Related]
16. The fifth edition of the WHO classification of mature B-cell neoplasms: open questions for research.
Coupland SE; Du MQ; Ferry JA; de Jong D; Khoury JD; Leoncini L; Naresh KN; Ott G; Siebert R; Xerri L;
J Pathol; 2024 Mar; 262(3):255-270. PubMed ID: 38180354
[TBL] [Abstract][Full Text] [Related]
17. B-ALL with synchronous MYC and BCL-2 rearrangement.
Attieh M; Asakrah S
Blood; 2023 Apr; 141(15):1894. PubMed ID: 37052936
[No Abstract] [Full Text] [Related]
18. Impact of MYC and BCL2 double expression on outcomes in primary CNS lymphoma: a UK multicenter analysis.
Poynton E; Chernucha E; Day J; Prodger C; Hopkins D; Rakesh P; O'Neill T; Thakrar N; Akarca A; Jamal E; Ali A; Kirkwood AA; Pomplun S; Marafioti T; Calaminici M; Greaves P; Chaganti S; McKay P; Smith J; Eyre TA; Martinez-Calle N; Cwynarski K; Fox CP; Okosun J
Blood Adv; 2024 Apr; 8(7):1772-1775. PubMed ID: 38039509
[No Abstract] [Full Text] [Related]
19. Variable Responses of MYC Translocation Positive Lymphoma Cell Lines To Different Combinations of Novel Agents: Impact of BCL2 Family Protein Expression.
Deng W; Clipson A; Liu H; Huang Y; Dobson R; Wang M; Johnson P; Du MQ
Transl Oncol; 2018 Oct; 11(5):1147-1154. PubMed ID: 30055346
[TBL] [Abstract][Full Text] [Related]
20. Navigating Lymphomas through BCR Signaling and Double-Hit Insights: Overview.
Argentiero A; Andriano A; Marziliano D; Desantis V
Hematol Rep; 2024 Mar; 16(1):164-178. PubMed ID: 38534887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
